Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26414869 | 0.83 | ALDH1A1 (0.41) | ALDH1A1TSHRFGFR4LMNALDHA | |
| SCHEMBL18473368 | 0.82 | ALDH1A1 (0.35) | ALDH1A1TSHRFGFR4 | |
| SCHEMBL20013480 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL18831062 | 0.76 | ALDH1A1 (0.44) | ALDH1A1TSHRFGFR4 | |
| SCHEMBL18559486 | 0.75 | LMNA (0.38) | ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL313661 | 0.74 | — | — | |
| SCHEMBL2492911 | 0.74 | — | — | |
| SCHEMBL19578524 | 0.74 | — | — | |
| SCHEMBL19980838 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNA | |
| SCHEMBL17733136 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9822102-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | OGFOD1, VASP, PNPO | ALDH1A1 1195/4885TSHR 3903/4885FGFR4 3971/4885 |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | ALDH1A1 1492/4885TSHR 3756/4885FGFR4 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.